Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

• DOI: 10.1002/alz.12545
• Publication Date: 2021-12-22T12:18:10Z
• Authors: Constance Delaby; Charlotte E. Teun...; Kaj Blennow; Daniel Alcolea; Ivan Arisi; Elodie Bouaziz Amar; Anne Beaume; Aurélie Bedel; Giovanni Bellomo; Edith Bigot‐Corbel; Maria Bjerke; Marie‐Céline Blan...; Mercè Boada; Olivier Bousiges; Miles D Chapman; Mari L. DeMarco; Mara D'Onofrio; Julien Dumurgier; Diane Dufour‐Rain...; Sebastiaan Engelb...; Hermann Esselmann; Anne Fogli; Audrey Gabelle; Elisabetta Galloni; Clémentine Gondolf; Frédérique Grandh...; Oriol Grau‐Rivera; Melanie Hart; Takeshi Ikeuchi; Andreas Jeromin; Kensaku Kasuga; Ashvini Keshavan; Michael Khalil; Peter Körtvelyessy; Agnieszka Kulczyn...; Jean‐Louis Laplanche; Piotr Lewczuk; Qiao‐Xin Li; Alberto Lleó; Catherine Malaplate; Marta Marquié; Colin L. Masters; Barbara Mroczko; Léonor Nogueira; Adelina Orellana; Markus Otto; Jean‐Baptiste Oudart; Claire Paquet; Federico Paolini ...; Lucilla Parnetti; Armand Perret‐Lia...; Katell Peoc'h; Koen Poesen; Albert Puig‐Pijoan; Isabelle Quadrio; Muriel Quillard‐M...; Benoit Rucheton; Susanna Schraen; Jonathan M. Schott; Leslie M. Shaw; Marc Suárez‐Calvet; Magda Tsolaki; Hayrettin Tumani; Chinedu T Udeh‐Momoh; Lucie Vaudran; Marcel M Verbeek; Federico Verde; Lisa Vermunt; Jonathan Vogelgsang; Jens Wiltfang; Henrik Zetterberg; Sylvain Lehmann
• Keywords: [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology; Consensus approach; Clinical Neurology; 610; tau Proteins; cerebrospinal fluid [Amyloid beta-Peptides]; DIAGNOSIS; RECOMMENDATIONS; Cerebrospinal fluid biomarkers; Alzheimer Disease; 616; CRITERIA; Humans; ddc:610; cerebrospinal fluid [Peptide Fragments]; clinical report; cerebrospinal fluid biomarkers; consensus approach; Science & Technology; Amyloid beta-Peptides; Featured Articles; 9. Industry and infrastructure; [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology; diagnosis [Alzheimer Disease]; Radboudumc 3: Disorders of movement DCMN: Donders Center for Medical Neuroscience; Alzheimer's disease; 16. Peace & justice; Clinical report; Peptide Fragments; 3. Good health; cerebrospinal fluid [Alzheimer Disease]; Alzheimer's disease; cerebrospinal fluid biomarkers; clinical report; consensus approach; harmonization; cerebrospinal fluid [Biomarkers]; cerebrospinal fluid [tau Proteins]; Harmonization; harmonization; Neurosciences & Neurology; Human medicine; Life Sciences & Biomedicine; Alzheimer’s disease; Biomarkers

AbstractIntroductionThe current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests.MethodsWe obtained a description of (pre‐)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients.ResultsThe (pre‐)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis.DiscussionThis is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.